Nano-X Imaging

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Neve Ilan, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nano-X Imaging reports progress in regulatory clearances and strategic partnerships

Nano-X Imaging showcased progress in regulatory clearances, commercialization efforts, strategic partnerships, and operational optimization during the Q4 2022 Earnings Call.
Despite challenges in regulatory compliance, expenses management, and market competition, the company's strengths in innovation, partnerships, and financial resilience position it well for future growth.
Opportunities for Nano-X Imaging include global expansion, technological advancements, cost efficiencies, and leveraging market demand for imaging solutions.
Overall, Nano-X Imaging's performance in Q4 2022 reflects a strategic focus on growth, innovation, and market expansion in the medical imaging industry.

Nano-X Imaging reports improved Q1 performance and expands global reach

Nano-X Imaging's Q1 2023 performance showed improvement with a reported net loss of $11.8 million and revenue of $2.4 million. The company is focusing on deploying Nanox.ARC globally, strengthening manufacturing capabilities, and expanding market reach through strategic partnerships. Challenges include managing expenses and driving revenue growth to achieve profitability.

Nanox Imaging reports Q2 results, eyes U.S. market growth

Nanox Imaging's Q2 2023 performance reflects investment in growth initiatives, with a focus on market expansion and product deployment.
The company faces financial challenges, including a significant net loss and accrued expenses related to an SEC investigation, necessitating prudent financial management.
Strategic strengths in the U.S. market entry, global commercialization efforts, and strong cash position position Nanox Imaging for future growth and market success.
Opportunities lie in upcoming Investor Day, FDA clearance for Nanox.ARC, and expansion in Africa, offering avenues for revenue growth and market leadership.

Nanox Imaging reports Q3 revenue growth and strategic advancements

Nanox Imaging's Q3 2023 performance showed revenue growth and strategic advancements. While facing financial challenges and potential execution hurdles, the company's focus on expansion and partnerships positions it for future growth.

Nanox Imaging reports Q4 loss, eyes global expansion and AI

Nanox Imaging's Q4 2023 performance showed a mix of revenue growth and strategic investments in technology and market expansion.
The company's strengths lie in its progress with regulatory clearances, commercialization efforts, and success in AI applications.
Challenges include slow AI adoption, implementation hurdles, and the need to overcome barriers to data sharing and transparency.
Opportunities exist in expanding HealthCCS usage, global market presence, and addressing AI adoption challenges for revenue growth.

Nanox Imaging reports Q1 loss, eyes global expansion and AI growth

Nanox Imaging's Q1 2024 performance reflects revenue generation from AI solutions and system sales amid challenges in gross profit margins and a notable net loss.
The company's strategic strengths in partnerships, product launches, and global expansions position it well for future growth and market competitiveness.
While facing challenges in cost management and profitability, Nanox Imaging holds opportunities in expanded indications, market expansions, and AI solutions deployment.

Nano-X Imaging reports Q2 losses, eyes growth through FDA clearances

Nano-X Imaging (NNOX) showcased progress in commercial and clinical fronts but faces challenges in narrowing losses and optimizing operations.
Strategic collaborations, FDA clearances, and global deployment offer opportunities for growth and market expansion.
The focus on transformative imaging solutions and commercial infrastructure acceleration underlines NNOX's commitment to innovation and market leadership.

Nanox Imaging reports mixed Q3 results amidst growth opportunities

Nanox Imaging reported mixed financial results with revenue of $3.0 million and a gross loss of $2.8 million, while achieving record revenue from USARAD business.
The company showcased strengths in technology deployment, partnerships, and clinical trials, but faces challenges in regulatory clearances and financial performance.
Opportunities exist in market expansion, revenue growth, and operational efficiency improvements to drive future success and profitability.
With a strong focus on innovation, partnerships, and market expansion, Nanox is poised for growth but needs to address regulatory hurdles and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Petach Tikva, Israel.

NVIDIA

As the artificial intelligence (AI) industry continues to evolve, Nvidia (NASDAQ: NVDA) has positioned itself as a key player, recording solid performances and climbing the ranks in terms of company size.

Nano-X Imaging stock jumps on Nvidia's strategic investments

SoundHound AI Inc

ARM Holdings PLC

Nvidia disclosed investments in Arm Holdings, SoundHound AI and more in its first-ever 13F SEC filing late Wednesday. ARM rose while SOUN stock soared.

Nvidia Discloses Stakes In Arm, SoundHound AI, Nano-X And More

Nanox's HealthFLD is pioneering the use of a fully automated AI software for liver attenuation analysis from CT scans that has received FDA 510(k) clearance for use in general population

Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver

PETACH TIKVA, Israel, Jan. 16, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced that the Company's founder and non-executive chairman, Ran Poliakine, passed away on Friday, Jan. 12, 2024, due to a medical condition. Mr. Poliakine was a serial entrepreneur who over the course of his 35-year career founded more than 20 companies, and gave rise to over 70 patents in his various fields of interest, including healthcare, social impact technology, the environment and industry.

Nanox Mourns Death of Its Founder, Ran Poliakine

NEW YORK , Dec. 1, 2023 /PRNewswire/ --  UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK   IN RE NANO-X SECURITIES LITIGATION   Case No. 1:21-cv-05517-RPK-PK     Hon.

Levi & Korsinsky, LLP and Pomerantz LLP Announce Proposed Settlement of Class Action Involving Purchasers of Nano-X Imaging Ltd. Securities

Nano-X Imaging Ltd (NASDAQ:NNOX ) Q3 2023 Earnings Conference Call November 28, 2023 8:30 AM ET Company Participants Erez Meltzer - CEO Ran Daniel - CFO Mike Cavanaugh - IR Conference Call Participants Jeff Cohen - Ladenburg Thalmann Ross Osborn - Cantor Fitzgerald Ben Haynor - Alliance Capital Partners Operator Good day, and thank you for standing by. Welcome to the Nano-X Q3 2023 Earnings Conference Call.

Nano-X Imaging Ltd (NNOX) Q3 2023 Earnings Call Transcript

Reports progress towards global supply chain development and commercial deployment Ended the third quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $95.6 million Management to host conference call and webcast Tuesday, November 28, 2023 at 8:30 AM ET Management to host investor day on December 4, 2023 NEVE ILAN, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2023 and provided a business update. Third Quarter 2023 Highlights and Recent Developments:   ● On September 29, 2023, the Company entered into a manufacture and supply agreement with Varex Imaging Corporation (“Varex,” Nasdaq: VREX), a leading innovator, designer and manufacturer of X-ray imaging components, under which Varex will supply X-ray tubes utilizing the Nanox digital X-ray source for the Nanox.ARC system.

Nanox Announces Third Quarter of 2023 Financial Results and Provides Business Update

NEVE ILAN, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2023 on November 28, 2023 at 8:30 a.m. ET. The Company also announced that it will hold its Investor Day on December 4, 2023, at the Nasdaq building in New York City.

Nanox to Report Third Quarter 2023 Financial Results on November 28, 2023 and Reschedules Investor Day for December 4, 2023

NEVE ILAN, Israel, Oct. 10, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that it is postponing the previously announced Investor Day scheduled for Tuesday, Oct. 17, 2023, at the Nasdaq in New York City. “It is with sadness that we announce the decision to postpone our Investor Day,” said Erez Meltzer, Chief Executive Officer of Nanox.

Nanox Continues Business as Planned, and Postpones Investor Day Scheduled for October 17, 2023

NEVE ILAN, Israel and SALT LAKE CITY, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company today announced the entrance into a manufacture and supply agreement with Varex Imaging Corporation (“Varex,” Nasdaq: VREX), a leading innovator, designer and manufacturer of X-ray imaging components, under which Varex will supply X-ray tubes utilizing the Nanox digital X-ray source for the Nanox.ARC system. The agreement was entered into after Varex completed, over the last several months, an assessment of Nanox's novel digital X-ray source.

Nanox Announces Strategic Manufacturing Agreement with Varex Imaging Corporation to Advance the Nanox.ARC Medical Imaging System

Nano-X Imaging and its founder Ran Poliakine agreed to pay nearly $1.1 million to settle U.S. Securities and Exchange Commission charges accusing the Israeli medical imaging company of negligently misleading investors about the cost to make its flagship product.

Israeli's Nano-X settles US SEC charges over costs of flagship imaging device

Beilinson Hospital in Israel used Nanox.AI's HealthCCSng solution to conduct study on routine chest CT scans to assess impact of AI-based coronary artery calcium (CAC) measurements

Nanox.AI's HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTs

Bionano Genomics

Novavax

Biotech companies can offer some of the most explosive returns for an investor. Small-cap biotech companies are known to shoot up 100% overnight and also to dump 50% in an instant as well.

Ticking Time Bombs: 3 Biotech Stocks to Dump Before the Damage Is Done

NEVE ILAN, Israel, Sept. 13, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced its participation in the Cantor Fitzgerald Global Healthcare Conference 2023, which will be held on September 26-28, 2023 at the InterContinental Barclay Hotel in New York City.

Nanox to Present at the Cantor Fitzgerald Global Healthcare Conference 2023 in September

Agenus

BioCryst Pharmaceuticals

Growth stocks have slumped in August. This broad sell-off has created some compelling buying opportunities.

3 Magnificent Growth Stocks to Buy on the Dip

Nano-X Imaging Ltd (NASDAQ:NNOX ) Q2 2023 Results Conference Call August 17, 2023 8:30 AM ET Company Participants Mike Cavanaugh - Investor Relations Erez Meltzer - Chief Executive Officer Ran Daniel - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Operator Good morning, and thank you for standing by. Welcome to the Nano-X Second Quarter 2023 Earnings Call.

Nano-X Imaging Ltd (NNOX) Q2 2023 Earnings Call Transcript

Reports progress towards global supply chain development Ended the second quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $80.3 million Management to host conference call and webcast Thursday, August 17, 2023 at 8:30 AM ET NEVE ILAN, Israel, Aug. 17, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2023 and provided a business update. Second Quarter 2023 Highlights and Recent Developments:   ●   On April 28, 2023, the Company received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) to market the Nanox.ARC (including the Nanox.CLOUD) as a stationary ‎X-ray ‎system ‎intended to produce tomographic images of the human musculoskeletal system adjunctive to conventional radiography, on adult patients.

Nanox Announces Second Quarter of 2023 Financial Results and Provides Business Update

NEVE ILAN, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX) will report its financial results for the second quarter ended June 30, 2023 before market open on Thursday, August 17, 2023. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update on the same day at 8:30 a.m. ET.

Nanox to Report Second Quarter 2023 Financial Results on August 17, 2023

Nano-X is working to multiply the value of its top line in 2024. Its stock price will likely follow its sales upward at least part of the way.

Got $2,500? Buying Shares of This Medical Device Stock Right Now Could Be a Smart Move

NEVE ILAN, Israel, July 24, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,142,858 of the Company's ordinary shares, par value NIS 0.01 per share (the “ordinary shares”), together with warrants to purchase up to 2,142,858 ordinary shares at a combined purchase price of $14.00 per share, in a registered direct offering. The warrants will have an exercise price of $19.00 per share, will be exercisable immediately upon issuance and will expire five years from issuance.

Nanox Announces $30 Million Registered Direct Offering

The Food and Drug Administration recently granted marketing clearance for the company's X-ray system. Nano-X believes it can make medical imaging more affordable and accessible.

Could Nano-X Imaging Stock Help You Become a Millionaire?

Nano-X now has approval from regulators in the U.S. to market its unique X-ray device. It'll be placing its systems mostly in places where there are few X-ray devices.

Where Will Nano-X Imaging Be in 3 Years?

Nano-X Imaging's share price has seen a significant increase due to its expansion of global operations and the development of a revolutionary X-ray machine. The company recently gained clearance from the US Food and Drug Administration to begin marketing Nanox.ARC, a major step towards operating as a functioning healthcare company. Despite the potential for high returns, investing in NNOX is considered risky due to the company's negative net income and high valuations, and the inherent uncertainty in biotech ventures.

Nano-X Imaging: A Very Exciting Opportunity That I Want To Be Part Of

Israeli medical tech firm Nano-X Imaging is the top-rated healthcare equipment stock as per Seeking Alpha's Quant Rating. We explore what's behind the hype and lay down a few concerns. We conclude with our thoughts on the valuations and the technicals.

Nano-X Imaging - Some Good, Some Bad

C3.ai

Nano-X Imaging and C3.ai are hot buys this year but were even hotter in 2021. These businesses are risky, however, and neither one is profitable right now.

News for Nano-X Imaging Stock (NNOX)